Table 1 Clinicopathologic characteristics of patient sample sets
From: The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer
Characteristics | Cohort 1 Training (total RNA-seq) | Cohort 2 Validation (NanoString) | RP cohort 3 Validation (NanoString) | Cohort 4 Liquid biopsies (NanoString) | |||
|---|---|---|---|---|---|---|---|
RP cohort 1 LPC (n = 126) | MPC (n = 17) | LPC (n = 35) | MPC (n = 54) | LPC (n = 191) | LPC (n = 21) | MPC (n = 6) | |
Sample type | RP | TURP | RP (n = 22), TRUSbx (n = 13) | TRUSbx | RP | Plasma/EVs | Plasma/EVs |
Median agea, years (IQR) | 65.1 (59.2–68.7) | NA | 69.4 (62.8–73.0) | 71.5 (67.9–74.1) | 64.2 (61.5–67.6) | 68.4 (64.9–72.8) | 73.7 (67.7–74.8) |
Median PSA at diagnosis (IQR) | 10.8 (7.7–17.9) | 46.0 (9.7–98.8) | 9.2 (6.3–16.5) | 30.0 (11.8–46.0) | 10.2 (7.1–5.8) | 9.1 (6.8–17.2) | NA |
Gleason Grade Groupb | |||||||
1 | 12 (9.5%) | 1 (5.9%) | 0 | 1 (1.9%) | 61 (31.9 %) | 1 (4.8%) | 0 |
2 | 68 (54.0%) | 1 (5.9%) | 13 (37.1%) | 1 (1.9%) | 105 (55.0 %) | 8 (38.1%) | 0 |
3 | 22 (17.5%) | 1 (5.9%) | 9 (25.7%) | 11 (20.4%) | 0 | 5 (23.8%) | 0 |
4 | 14 (11.1%) | 5 (29.4%) | 3 (8.6%) | 23 (42.6%) | 20 (10.5%) | 4 (19.0%) | 0 |
5 | 9 (7.1%) | 8 (47.1%) | 10 (28.6%) | 17 (31.5%) | 5 (2.6%) | 2 (9.5%) | 3 (50%) |
Unknown | 1 (0.8%) | 1 (5.9%) | 0 | 1 (1.9%) | 0 | 1 (4.8%) | 3 (50%) |
T-stagec | |||||||
T1 | 0 | 0 | 8 (22.9%) | 3 (5.6%) | 0 | 4 (19.0%) | 1 (16.7%) |
T2 | 75 (59.5%) | 2 (11.8%) | 12 (34.3%) | 15 (27.8) | 140 (73.3 %) | 13 (61.9%) | 3 (50%) |
T3 | 49 (38.9%) | 2 (11.8%) | 15 (42.9%) | 33 (61.1%) | 49 (25.7 %) | 2 (9.5%) | 2 (33.3%) |
T4 | 1 (0.8%) | 1 (5.9%) | 0 | 2 (3.7%) | 1 (0.3 %) | 0 | 0 |
Unknown | 1 (0.8%) | 12 (70.6%) | 0 | 1 (1.9%) | 1 (0.5%) | 2 (9.5%) | 0 |
CAPRA-S risk nomogram | |||||||
Low risk | 29 (23.0%) | NA | NA | NA | 47 (24.6%) | NA | NA |
Intermediate risk | 60 (47.6%) | NA | NA | NA | 100 (52.4%) | NA | NA |
High risk | 34 (27.0%) | NA | NA | NA | 36 (18.8%) | NA | NA |
Unknown | 3 (2.4%) | 8 (4.2%) | |||||
Surgical margin status | |||||||
Negative | 82 (65.1%) | NA | NA | NA | 140 (73.3 %) | NA | NA |
Positive | 41 (32.5%) | NA | NA | NA | 51 (26.7 %) | NA | NA |
Unknown | 3 (2.4%) | 0 | |||||
Recurrence status | |||||||
Recurrence-free | 75 (59.5%) | NA | NA | NA | 108 (56.5 %) | NA | NA |
Biochemical recurrence | 50 (39.7%) | NA | NA | NA | 83 (43.5 %) | NA | NA |
Unknown | 1 (0.8%) | 0 | |||||
Progression to MPC | |||||||
Progression free | NA | NA | NA | NA | 180 | NA | NA |
MPC progression | NA | NA | NA | NA | 11 | NA | NA |
Median follow-up time, months (IQR) | 65.9 (45.3–102.6) | NA | 19.9 (14.2–22.7) | NA | 125.3 (98.8–141.7) | NA | NA |
Survival status | |||||||
Alive | 110 (87.3%) | NA | NA | NA | 155 (81.2%) | NA | NA |
Dead | 16 (12.7%) | NA | NA | NA | 36 (18.8%) | NA | NA |
Non-malignant samples | AN (n = 31, from LPC patients) | AN (n = 22, from 20 LPC and 2 MPC patients) | Control (n = 27, cancer-free at initial TRUSbx) | ||||
Median agea(IQR) | 63.4 (58.1–66.5) | 68.6 (61.7–71.8) | 63.9 (58.5–68.3) | ||||